We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology
Due to their unrivaled tumor specificity, our antibodies can be developed into different mechanisms of action. Together with our partners, we strive to combine our antibodies with complementary technologies and to fully exploit their capabilities to develop novel first-in-class therapies for cancer patients with unmet medical needs. The foundation of all of our successful partnerships is a shared understanding of our values and vision. We are committed to our partners and our open and collaborative spirit fosters successful partnerships.
Byondis: Based on a platform access agreement signed in 2021, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
Daiichi Sankyo: Based on a worldwide licensing agreement signed in 2018, Daiichi Sankyo develops an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody GT-00A.
LegoChem Biosciences: LCB and Glycotope have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies. Upon successful completion of a feasibility study, LCB has the right to exercise an option for worldwide exclusive rights to develop and commercialize the selected antibody as ADC.
Medizinische Hochschule Hannover: The MHH and Glycotope have joined forces to research the suitability of carbohydrate antigens for CAR-T development.
Charité Comprehensive Cancer Center: The partnership between Glycotope and the Charité Comprehensive Cancer Center has existed for many years. During this time, a wide variety of projects have been carried out jointly to advance cancer treatment.
Fraunhofer Institute for Cell Therapy and Immunology: Various research projects.